Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Juin

Showing results (51-60 of 70) with videos related to

Pageof 7
Sort By:
Cell Death & Disease|February 5, 2016
Constitutive p53 heightens mitochondrial apoptotic priming and favors cell death induction by BH3 mimetic inhibitors of BCL-xLJ Le Pen, L Maillet, K Sarosiek, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 19, 2004
Dose-finding study of weekly 24-h continuous infusion of 5-fluorouracil associated with alternating oxaliplatin or irinotecan in advanced colorectal cancer patientsL Cals, O Rixe, E François, et al.
Oncogenesis|October 24, 2017
DNA methylation signal has a major role in the response of human breast cancer cells to the microenvironmentP Mathot, M Grandin, G Devailly, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|December 9, 2010
Mitochondrial targeting by use of lipid nanocapsules loaded with SV30, an analogue of the small-molecule Bcl-2 inhibitor HA14-1M Weyland, F Manero, A Paillard, et al.
Computers in Biology and Medicine|December 14, 2020
Development of an absolute assignment predictor for triple-negative breast cancer subtyping using machine learning approachesFadoua Ben Azzouz, Bertrand Michel, Hamza Lasla, et al.
Cell Death & Disease|October 10, 2014
miR-491-5p-induced apoptosis in ovarian carcinoma depends on the direct inhibition of both BCL-XL and EGFR leading to BIM activationC Denoyelle, B Lambert, M Meryet-Figuière, et al.
Molecular and Cellular Biology|December 22, 2010
Bax activation by engagement with, then release from, the BH3 binding site of Bcl-xLF Gautier, Y Guillemin, P F Cartron, et al.
Cell Death & Disease|August 9, 2025
MCL-1 as a molecular switch between myofibroblastic and pro-angiogenic features of breast cancer-associated fibroblastsChloé C Lefebvre, Philippine Giowachini, Jennifer Derrien, et al.
EMBO Reports|December 14, 2017
E2F1 interacts with BCL-xL and regulates its subcellular localization dynamics to trigger cell deathCéline Vuillier, Steven Lohard, Aurélie Fétiveau, et al.
British Journal of Cancer|September 19, 2007
Concomitant intensive chemoradiotherapy induction in non-metastatic inflammatory breast cancer: long-term follow-upD Genet, C Lejeune, P Bonnier, et al.
Pageof 7

Showing results (51-60 of 70) with videos related to

Sort By:
Pageof 7
Cell Death & Disease|February 5, 2016
Constitutive p53 heightens mitochondrial apoptotic priming and favors cell death induction by BH3 mimetic inhibitors of BCL-xLJ Le Pen, L Maillet, K Sarosiek, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 19, 2004
Dose-finding study of weekly 24-h continuous infusion of 5-fluorouracil associated with alternating oxaliplatin or irinotecan in advanced colorectal cancer patientsL Cals, O Rixe, E François, et al.
Oncogenesis|October 24, 2017
DNA methylation signal has a major role in the response of human breast cancer cells to the microenvironmentP Mathot, M Grandin, G Devailly, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|December 9, 2010
Mitochondrial targeting by use of lipid nanocapsules loaded with SV30, an analogue of the small-molecule Bcl-2 inhibitor HA14-1M Weyland, F Manero, A Paillard, et al.
Computers in Biology and Medicine|December 14, 2020
Development of an absolute assignment predictor for triple-negative breast cancer subtyping using machine learning approachesFadoua Ben Azzouz, Bertrand Michel, Hamza Lasla, et al.
Cell Death & Disease|October 10, 2014
miR-491-5p-induced apoptosis in ovarian carcinoma depends on the direct inhibition of both BCL-XL and EGFR leading to BIM activationC Denoyelle, B Lambert, M Meryet-Figuière, et al.
Molecular and Cellular Biology|December 22, 2010
Bax activation by engagement with, then release from, the BH3 binding site of Bcl-xLF Gautier, Y Guillemin, P F Cartron, et al.
Cell Death & Disease|August 9, 2025
MCL-1 as a molecular switch between myofibroblastic and pro-angiogenic features of breast cancer-associated fibroblastsChloé C Lefebvre, Philippine Giowachini, Jennifer Derrien, et al.
EMBO Reports|December 14, 2017
E2F1 interacts with BCL-xL and regulates its subcellular localization dynamics to trigger cell deathCéline Vuillier, Steven Lohard, Aurélie Fétiveau, et al.
British Journal of Cancer|September 19, 2007
Concomitant intensive chemoradiotherapy induction in non-metastatic inflammatory breast cancer: long-term follow-upD Genet, C Lejeune, P Bonnier, et al.
Pageof 7